Gene expression profiling of anticancer immune responses

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 3, 2004, Pages 288-295

  Wang, Ena ^a   Panelli, Monica C ^a   Monsurró, Vladia ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Human leukocyte antigen; IL 2 immunoresponsiveness; Polymorphism; T cell

Indexed keywords

CD27 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; FAS LIGAND; GAMMA INTERFERON; GRANZYME A; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOME ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; MELANOMA; MICROENVIRONMENT; NONHUMAN; PROSTATE CANCER; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNOLOGY; TUMOR REJECTION;

ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY; NEOPLASMS; POLYMORPHISM, GENETIC; T-LYMPHOCYTES;

EID: 3242887932     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A: Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med (1989) 170(3):797-810.
2. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA: Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol (1992) 148(2):638-643.
3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C et al. Highdose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1998) 17(7):2105-2116.
4. Yang JC, Rosenberg SA: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am (1997) 3(Suppl 1):S79-S84.
5. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643-1647.
6. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA (1997) 94(5):1914-1918.
7. Old LJ, Chen YT: New paths in human cancer serology. J Exp Med (1998) 187(8):1163-1167.
8. Boon T, Coulie PG, van den Eynde B: Tumor antigens recognized by T cells. Immunol Today (1997) 18(6):267-268.
9. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today (1997) 18(4):175-182.
10. Marincola FM, Ferrone S: Immunotherapy of melanoma: The good news, the bad ones and what to do next. Semin Cancer Biol (2003) 13(6):387-389.
11. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am (1997) 3(1):37-44.
12. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 4(3):321-327.
13. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol (2000) 74:181-273.
14. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S: Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 24(6):335-342.
15. Monsurro V, Wang E, Panelli MC, Nagorsen D, Jin P, Katia Z, Smith K, Ngalame Y, Even J, Marincola FM: Active-specific immunization against melanoma: Is the problem at the receiving end? Semin Cancer Biol (2003) 13(6):473-480.
16. Marincola FM: Translational medicine: A two-way road. J Transl Med (2003) 1(1):1.
17. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature (1998) 396(6712):643-649.
18. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: From immunosurvellance to tumor escape. Nat Immunol (2002) 3(11):991-998.
19. Jin P, Wang E: Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling. J Transl Med (2003) 1(1):8.
20. Wang E, Marincola FM: cDNA arrays and the enigma of melanoma immune responsiveness. Cancer J (2001) 7(1):16-24.
21. Aichele P, Brduscha-Riem K, Oehen S, Odermatt B, Zinkernagel RM, Hengartner H, Pircher H: Peptide antigen treatment of naive and virus-immune mice: Antigen-specific tolerance versus immunopathology. Immunity (1997) 6(5):519-529.
22. Zinkernagel RM: Immunology taught by viruses. Science (1996) 271(5246):173-178.
23. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM: Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA (1999) 96(5):2233-2238.
24. Fuchs EJ, Matzinger P: Is cancer dangerous to the immune system? Semin Immunol (1996) 8(5):271-280.
25. Matzinger P: Introduction to the series. Danger model of immunity. Scand J Immunol (2001) 54(1-2):2-3.
26. Schwab ED, Pienta KJ: Cancer as a complex adaptive system. Med Hypotheses (1996) 47(3):235-241.
27. Cucuianu A: Chaos in cancer? Nat Med (1998) 4(12):1342-1343.
28. Dalgleish A: The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines. Q J Med (1999) 92(6):347-359.
29. Wang E, Panelli MC, Marincola FM: Genomic analysis of cancer. Princ Pract Oncol (2003) 17(9):1-16.
30. Wang E, Marincola FM: A natural history of melanoma: Serial gene expression analysis. Immunol Today (2000) 21(12):619-623.
31. Andersen MH, Gehl J, Reker S, Pedersen LO, Becker JC, Geertsen P, thor Straten P: Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol (2003) 13(6):449-459.
32. Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M: Immunotherapy of melanoma. Semin Cancer Biol (2003) 13(6):391-400.
33. Horig H, Kaufman HL: Local delivery of poxvirus vaccines for melanoma. Semin Cancer Biol (2003) 13(6):417-422.
34. Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U: Rational peptide-based tumor vaccine development and T cell monitoring. Semin Cancer Biol (2003) 13(6):423-429.
35. Talebi T, Weber JS: Peptide vaccine trials for melanoma: Preclinical background and clinical results. Semin Cancer Biol (2003) 13(6):431-438.
36. Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK: Dendritic cells as vectors for immunotherapy of cancer. Semin Cancer Biol (2003) 13(6):439-447.
37. Speiser DE, Pittet MJ, Rimoldi D, Guillame P, Luescher IF, Lienard D, Lejeune F, Cerottini J-C, Romero P: Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor specific T cells. Semin Cancer Biol (2003) 13(6):461-472.
38. Kaech SM, Hemby S, Kersh E, Ahmed R: Molecular and functional profiling of memory CD8 T-cell differentiation. Cell (2002) 111(6):837-851.
39. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol (2003) 4(3):225-234.
40. van Baarle D, Kostehse S, van Oers MH, Hamann D, Miedema F: Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol (2002) 23(12):586-591.
41. Monsurro V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM: Functional heterogeneity of vaccine-induced CD8+ T cells. J Immunol (2002) 168(11):5933-5942.
42. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM: High-fidelity mRNA amplification for gene profiling. Nat Biotechnol (2000) 18(4):457-459.
43. Wang E, Marincola FM: Amplification of small quantities of mRNA for transcript analysis. In: DNA Arrays - A Molecular Cloning Manual. Bowtell D, Sambrook J (Eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (2002):204-213.
44. Kammula US, Lee K-H, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol (1999) 163(12):6867-6875.
45. Panelli MC, Riker A, Kammula U, Wang E, Lee K-H, Rosenberg SA, Marincola FM: Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol (2000) 164(1):495-504.
46. 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer (1994) 73(6 ):1731-1737.
47. Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM: Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol (2001) 167(3):1809-1820.
48. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 62(13):3581-3586.
49. Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA, Klein H, Marincola FM: Gene-expression profiling of the response of peripheral mononuclear cells and melanoma metastases in response to systemic IL-2 administration. Genome Biol (2002) 3(7):RESEARCH0035.
50. Wang E, Marincola FM, Stroncek D: Human leukocyte antigen (HLA) and human neutrophil antigen (HNA) systems. In: Hematology: Basic Principles and Practice. Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (Eds), Elsevier Science, Philadelphia, PA, USA (2003).
51. Rubin JT, Adams SD, Simonis T, Lotze MT: HLA polymorphism and response to IL-2 bases therapy in patients with melanoma. Proc Soc Biol Ther Annu Meet (1991) 1:18.
52. Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR: HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol (1995) 18(4):242-252.
53. Lee JE, Reveille JD, Ross MI, Platsoucas CD: HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer (1994) 59(4):510-513.
54. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM: Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun (2002) 3(4):229-232.
55. Howell WM, Calder PC, Grimble RF: Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc (2002) 61(4):447-456.
56. Wang E, Adams S, Zhao Y, Panelli M, Simon R, Klein H, Marincola FM: A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings. J Transl Med (2003) 1(1):4.
57. Marincola FM: Mechanisms of immune escape and immune tolerance. In: Principles and Practice of the Biologic Therapy of Cancer. Rosenberg SA (Ed), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2000):601-617.
58. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 406(6795):536-540.
59. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM: The dual role of IL-10. Trends Immunol (2003) 24(1):36-43.
60. Taniguchi T: Transcription factors IRF-1 and IRF-2: Linking the immune responses and tumor suppression. J Cell Physiol (1997) 173(2):128-130.
61. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D: Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 197(8):1017-1028.
62. Hanahan D, Lanzavecchia A, Mihich E: Fourteenth Annual Pezcoller Symposium: The novel dichotomy of immune interactions with tumors. Cancer Res (2003) 63(11):3005-3008.
63. Margolin KA: Interleukin-2 in the treatment of renal cancer. Semin Oncol (2000) 27(2):194-203.
64. Cotran RS, Pober JS, Gimbrone MA Jr, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT: Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol (1988) 140(6):1883-1888.
65. Kasid A, Director EP, Rosenberg SA: Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol (1989) 143(2):736-739.
66. Panelli MC, White R, Foster M, Martin B, Wang E, Smith K, Marincola FM, Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med (2004): 2(1):17.